沃森生物(300142.SZ)：收到水痘减毒活疫苗《药物临床试验批准通知书》

Core Viewpoint - Watson Bio (300142.SZ) has received approval from the National Medical Products Administration for a clinical trial of its live attenuated varicella vaccine, marking a significant step in its vaccine development efforts [1] Group 1: Clinical Trial Approval - The clinical trial approval notice for the varicella vaccine was issued recently, with the approval number 2026LP00378 [1] - The vaccine is classified as a preventive biological product and is intended for the prevention of chickenpox [1] - The approval confirms that the vaccine meets the registration requirements as per the relevant laws and regulations, allowing clinical trials to commence [1] Group 2: Vaccine Development - The vaccine is developed using a live attenuated strain of the varicella-zoster virus (VZV) and is produced using a freeze-drying process [1] - Upon administration, the vaccine is designed to stimulate the immune system to produce immunity against the varicella-zoster virus, thereby preventing chickenpox [1] - The clinical trials must be conducted within three years from the date of approval, with the notice becoming invalid if no informed consent is obtained from participants within that timeframe [1]